The Montrium Connect platform empowers Medpace to centralize and standardize clinical records
MONTREAL, QC - Cincinnati-based CRO Medpace has selected Montrium's eTMF Connect and RegDocs Connect solutions for the management of Medpace' clinical and regulatory documentation, improving clinical trial efficiency via a cloud-based document solution and enhancing their technology platform. Combined, these solutions form a comprehensive Electronic Document Management System (EDMS). "Medpace selected Montrium after evaluating several EDMS solutions available on the market. What we liked the most about the eTMF Connect & RegDocs Connect solutions, provided on the Montrium Connect platform, was the synergy between the system functionality and how we currently manage our clinical trials," said Gary Rickels, Director of IT Infrastructure & Support at Medpace. "Montrium is a well-known knowledge leader for the CRO industry, and comes with a strong reputation for providing a robust solution set and supporting implementation & validation services. The added value in built-in configurable workflows, PDF conversion capability, a true EDM and TMF model structure built in, as well as digital signature technology will give us the platform we need to continue our extensive growth. " The Montrum Connect platform provides a collaborative environment for organizations engaging in clinical activity, allowing them to manage centrally all of the clinical, regulatory and quality documentation required by the regulatory agencies. Montrium Connect can be deployed in an on-premise deployment or via Montrium's qualified GxP cloud hosted on Microsoft Azure. "Contract Research Organizations (CROs) play a critical role in clinical trials, and have emerged as integral stakeholders in the compilation of Trial Master Files and electronic submissions," said Paul Fenton, President & CEO of Montrium. "We are excited to have been selected as a strategic partner of Medpace to help them empower their continued growth. Partnering with a clinical trial powerhouse such as Medpace attests to the maturity and comprehensiveness of our growing solution set."
Additional Information
About Montrium
Montrium is a global leader in cloud-based document & quality management solutions and GxP consulting services for the Life Sciences. Operating in the Life Sciences for over 10 years, Montrium has been successfully helping organizations implement and maintain technology to improve their business processes and increase compliance. Montrium currently serves over 7500 satisfied users in over 20 countries. For more information on the products and services Montrium provides, please visit their website:
www.montrium.com
About Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,300 people across 35 countries. For more information visit
www.medpace.com
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.